Encapsulation of Cryptococcus neoformans impairs antigen-specific T-cell responses
about
Virulence factors of medically important fungiFungicidal properties of defensin NP-1 and activity against Cryptococcus neoformans in vitroChloroquine induces human mononuclear phagocytes to inhibit and kill Cryptococcus neoformans by a mechanism independent of iron deprivationPotent antifungal effects of a new derivative of partricin A in a murine model of cerebral cryptococcosisDifferential host susceptibility to intracerebral infections with Candida albicans and Cryptococcus neoformans.The cell wall and membrane of Cryptococcus neoformans possess a mitogen for human T lymphocytes.The capsule of Cryptococcus neoformans reduces T-lymphocyte proliferation by reducing phagocytosis, which can be restored with anticapsular antibodyLymphocyte transformation assay for C neoformans antigen is not reliable for detecting cellular impairment in patients with neurocryptococcosisAnticryptococcal resistance in the mouse brain: beneficial effects of local administration of heat-inactivated yeast cells.Antibodies to Cryptococcus neoformans glucuronoxylomannan enhance antifungal activity of murine macrophagesIngestion of acapsular Cryptococcus neoformans occurs via mannose and beta-glucan receptors, resulting in cytokine production and increased phagocytosis of the encapsulated formDownregulation by cryptococcal polysaccharide of tumor necrosis factor alpha and interleukin-1 beta secretion from human monocytesAntibody immunity and invasive fungal infectionsCryptococcus neoformans and cryptococcal glucuronoxylomannan, galactoxylomannan, and mannoprotein induce different levels of tumor necrosis factor alpha in human peripheral blood mononuclear cellsStructure and biological activities of acapsular Cryptococcus neoformans 602 complemented with the CAP64 genePhenotypic switching of Cryptococcus neoformans occurs in vivo and influences the outcome of infectionExperimental model of intracerebral infection with Cryptococcus neoformans: roles of phagocytes and opsonization.Protective murine monoclonal antibodies to Cryptococcus neoformansCryptococcus gattii: An Emerging Cause of Fungal Disease in North America.The capsule of the fungal pathogen Cryptococcus neoformans.Cryptococcal polysaccharides induce L-selectin shedding and tumor necrosis factor receptor loss from the surface of human neutrophils.Encapsulation of Cryptococcus neoformans with glucuronoxylomannan inhibits the antigen-presenting capacity of monocytes.Tissue localization of Cryptococcus neoformans glucuronoxylomannan in the presence and absence of specific antibodySurfactant protein D increases phagocytosis of hypocapsular Cryptococcus neoformans by murine macrophages and enhances fungal survival.Polysaccharide antigens of the capsule of Cryptococcus neoformans.Synergism between the antifungal agents amphotericin B and alkyl glycerol ethers.Effect of polysaccharide capsule and methods of preparation on human lymphocyte proliferation in response to Cryptococcus neoformans.What makes Cryptococcus neoformans a pathogen?Activation of macrophages and expansion of specific T lymphocytes in the lungs of mice intratracheally inoculated with Cryptococcus neoformans.
P2860
Q24683790-302C9001-8C2C-469E-B7D9-2F09C02BE67BQ28369533-B76548E2-6200-4E4F-B981-A1A4FB223F80Q28379104-7134F540-2B34-4A80-BE2F-84B913DB1653Q28379505-1FB92E41-91BA-4012-A957-1CA60FC93A03Q33605733-79D8AA90-89D7-4E82-A005-9FAE540D7BC9Q34000431-3A87E94D-3A19-458C-877B-6A8CC04F93ADQ34001769-8324C7B3-C4FE-4CF5-B490-FC8ABA2F1FDDQ34461657-87676FC2-079B-42AC-8E39-C8FBED3FFA11Q34532590-23C63A2C-F644-46B0-9D4A-D4EEE95C8F61Q35386000-AC4F4818-92C7-4C06-BA4D-3C1431B830E0Q35422948-A634A8B3-B04A-4D20-8B18-2F7F669A84FDQ35427625-AA9472DA-C0C1-4B1B-96CE-EBC82C26D82AQ35447692-F762B48B-56A6-47B0-A43A-4246A2663B73Q35534083-D899F29C-35E6-4483-8AD9-1D8860F2847EQ35546019-A303D242-251E-48FD-97FD-6C64699DD231Q36042949-7F02FEC4-5456-4F98-B56E-C87C03E21B15Q36950530-E185D341-24FC-4D32-8E3D-0726E3D1C1F3Q36969771-2973FB9D-39B7-4BA3-99DD-6DCFF6C37741Q37201768-8926A9D0-A5D4-4CC2-B3C6-8DB245AB9DB7Q37337879-CFCD6DC4-C189-4BE7-88AE-1AE3B84CBB80Q37351685-FD6BCCD8-65B6-4DEF-B345-EB70077D9D12Q39569976-48C033DD-4AF8-476A-8382-A7700E6C9B01Q39822906-2373D73D-69BD-4AD9-A0AD-168EA872A88CQ39849808-9B475BC2-7DAE-47F5-B212-6FCF6EC38B2BQ39859915-93A04EB3-A84F-455B-83F2-B1CDFBD4EACAQ40285811-0DA0B75A-FBAE-4B6E-B589-D44960B667F7Q40373891-32A45F29-BF96-494E-BB68-A422436E4DE6Q41695186-6EC2CCEC-F8BD-401B-BF1A-541E6F143F7CQ42491239-C2800B32-2DCB-44A7-8F85-E1D213CA335A
P2860
Encapsulation of Cryptococcus neoformans impairs antigen-specific T-cell responses
description
1991 nî lūn-bûn
@nan
1991年の論文
@ja
1991年論文
@yue
1991年論文
@zh-hant
1991年論文
@zh-hk
1991年論文
@zh-mo
1991年論文
@zh-tw
1991年论文
@wuu
1991年论文
@zh
1991年论文
@zh-cn
name
Encapsulation of Cryptococcus neoformans impairs antigen-specific T-cell responses
@en
type
label
Encapsulation of Cryptococcus neoformans impairs antigen-specific T-cell responses
@en
prefLabel
Encapsulation of Cryptococcus neoformans impairs antigen-specific T-cell responses
@en
P2860
P1476
Encapsulation of Cryptococcus neoformans impairs antigen-specific T-cell responses
@en
P2093
G J Bancroft
H L Collins
P2860
P304
P407
P577
1991-11-01T00:00:00Z